The impact of testosterone replacement therapy on glycemic control, vascular function, and components of the metabolic syndrome in obese hypogonadal men with type 2 diabetes

References

• Grossmann M, Thomas MC, Panagiotopoulos S, et al. Low testosterone levels are common and associated with insulin resistance in men with diabetes. J Clin Endocrinol Metab. 2008;93:1834–1840.
   PubMed Web of Science ®Google Scholar
• Kapoor D, Goodwin E, Channer KS, et al. Testosterone replacement therapy improves insulin resistance, glycaemic control, visceral adiposity and hypercholesterolaemia in hypogonadal men with type 2 diabetes. Eur J Endocrinol. 2006;154:899–906.
   PubMed Web of Science ®Google Scholar
• Grossmann M. Low testosterone in men with type 2 diabetes: significance and treatment. J Clin Endocrinol Metab. 2011;96:2341–2353.
   PubMed Web of Science ®Google Scholar
• Dandona P, Dhindsa S, Chaudhuri A, et al. Hypogonadotrophic hypogonadism in type 2 diabetes, obesity and the metabolic syndrome. Curr Mol Med. 2008;8:816–828.
   PubMedGoogle Scholar
• Dandona P, Dhindsa S, Chandel A, et al. Hypogonadotropic hypogonadism in men with type 2 diabetes. Postgrad Med. 2009;121:45–51.
   PubMed Web of Science ®Google Scholar
• Jones TH. Effects of testosterone on type 2 diabetes and components of the metabolic syndrome. J Diabetes. 2010;2:146–156.
   PubMed Web of Science ®Google Scholar
• Jones TH, Arver S, Behre HM, et al. Testosterone replacement in hypogonadal men with type 2 diabetes and/or metabolic syndrome (the TIMES2 study). Diabetes Care. 2011;34:828–837.
   PubMed Web of Science ®Google Scholar
• Boyanov MA, Boneva Z, Christov VG. Testosterone supplementation in men with type 2 diabetes, visceral obesity and partial androgen deficiency. Aging Male. 2003;6:1–7.
   PubMedGoogle Scholar
• Kalinchenko SY, Tishova YA, Mskhalaya GJ, et al. Effects of testosterone supplementation on markers of the metabolic syndrome and inflammation in hypogonadal men with the metabolic syndrome: the double‐blinded placebo‐controlled Moscow study. Clin Endocrinol (Oxf). 2010;73:602–612.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Brune M, Nieschlag E. Vascular reactivity in hypogonadal men is reduced by androgen substitution. J Clin Endocrinol Metab. 2002;87:5030–5037.
   PubMed Web of Science ®Google Scholar
• Basaria S, Harman S, Travison TG, et al. Effects of testosterone administration for 3 years on subclinical atherosclerosis progression in older men with low or low-normal testosterone levels: a randomized clinical trial. JAMA. 2015;314:570–581.
   PubMed Web of Science ®Google Scholar
• Bernini G, Versari D, Moretti A, et al. Vascular reactivity in congenital hypogonadal men before and after testosterone replacement therapy. J Clin Endocrinol Metab. 2006;91:1691–1697.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Morris PD, et al. Low serum testosterone and increased mortality in men with coronary heart disease. Heart. 2010;96:1821.
   PubMed Web of Science ®Google Scholar
• Feldman HA, Longcope C, Derby CA, et al. Age trends in the level of serum testosterone and other hormones in middle-aged men: longitudinal results from the Massachusetts male aging study. J Clin Endocrinol Metab. 2002;87:589–598.
   PubMed Web of Science ®Google Scholar
• Zitzmann M, Vorona E, Wenk M, et al. Testosterone administration decreases carotid artery intima media thickness as a marker of impaired vascular integrity in middle-aged overweight men. J Mens Health. 2009;6:243.
   Web of Science ®Google Scholar
• Cao J, Li J, Hao W, et al. Correlation of sex hormone and androgen receptor with diabetes mellitus in elderly men. Aging Male. 2011;14:162–167.
   PubMed Web of Science ®Google Scholar
• Jones RD, Pugh PJ, Jones TH, et al. The vasodilatory action of testosterone: a potassium-channel opening or a calcium antagonistic action? Br J Pharmacol. 2003;138:733–744.
   PubMed Web of Science ®Google Scholar
• Akishita M, Hashimoto M, Ohike Y, et al. Low testosterone level is an independent determinant of endothelial dysfunction in men. Hypertens Res. 2007;30:1029.
   PubMed Web of Science ®Google Scholar
• Vigen R, O’Donnell CI, Barón AE, et al. Association of testosterone therapy with mortality, myocardial infarction, and stroke in men with low testosterone levels. JAMA 2013;310:1829–1836.
   PubMed Web of Science ®Google Scholar
• Finkle WD, Greenland S, Ridgeway GK, et al. Increased risk of non-fatal myocardial infarction following testosterone therapy prescription in men. Gong Y, editor. PLoS One. 2014;9:e85805.
   PubMed Web of Science ®Google Scholar
• Shores MM, Smith NL, Forsberg CW, et al. Testosterone treatment and mortality in men with low testosterone levels. J Clin Endocrinol Metab. 2012;97:2050–2058.
   PubMed Web of Science ®Google Scholar
• Muraleedharan V, Marsh H, Kapoor D, et al. Testosterone deficiency is associated with increased risk of mortality and testosterone replacement improves survival in men with type 2 diabetes. Eur J Endocrinol. 2013;169:725–733.
   PubMed Web of Science ®Google Scholar
• Panach-Navarrete J, Martínez-Jabaloyas JM. The influence of comorbidities on the aging males’ symptoms scale in patients with erectile dysfunction. Aging Male. 2017;20:146–152.
   PubMed Web of Science ®Google Scholar
• Yassin A, Nettleship JE, Talib RA, et al. Effects of testosterone replacement therapy withdrawal and re-treatment in hypogonadal elderly men upon obesity, voiding function and prostate safety parameters. Aging Male. 2016;19:64–69.
   PubMed Web of Science ®Google Scholar
• Almehmadi Y, Yassin D-J, Yassin AA. Erectile dysfunction is a prognostic indicator of comorbidities in men with late onset hypogonadism. Aging Male. 2015;18:186–194.
   PubMed Web of Science ®Google Scholar
• Tajar A, Huhtaniemi IT, O’Neill TW, et al. Characteristics of androgen deficiency in late-onset hypogonadism: results from the European male aging study (EMAS). J Clin Endocrinol Metab. 2012;97:1508–1516.
   PubMed Web of Science ®Google Scholar
• de Ronde W, van der Schouw YT, Pols HAP, et al. Calculation of bioavailable and free testosterone in men: a comparison of 5 published algorithms. Clin Chem. 2006;52:1777.
   PubMed Web of Science ®Google Scholar
• Irie Y, Katakami N, Kaneto H, et al. Maximum carotid intima-media thickness improves the prediction ability of coronary artery stenosis in type 2 diabetic patients without history of coronary artery disease. Atherosclerosis. 2012;221:438–444.
   PubMed Web of Science ®Google Scholar
• Raitakari OT, Celermajer DS. Flow-mediated dilatation. Br J Clin Pharmacol. 2000;50:397–404.
   PubMed Web of Science ®Google Scholar
• Svartberg J, Agledahl I, Figenschau Y, et al. Testosterone treatment in elderly men with subnormal testosterone levels improves body composition and BMD in the hip. Int J Impot Res. 2008;20:378.
   PubMed Web of Science ®Google Scholar
• Allan CA, Strauss BJG, Burger HG, et al. Testosterone therapy prevents gain in visceral adipose tissue and loss of skeletal muscle in nonobese aging men. J Clin Endocrinol Metab. 2008;93:139–146.
   PubMed Web of Science ®Google Scholar
• Salman M, Yassin D-J, Shoukfeh H, et al. Early weight loss predicts the reduction of obesity in men with erectile dysfunction and hypogonadism undergoing long-term testosterone replacement therapy. Aging Male. 2017;20:45–48.
   PubMed Web of Science ®Google Scholar
• Francomano D, Bruzziches R, Barbaro G, et al. Effects of testosterone undecanoate replacement and withdrawal on cardio-metabolic, hormonal and body composition outcomes in severely obese hypogonadal men: a pilot study. J Endocrinol Investig. 2014;37:401–411.
   PubMed Web of Science ®Google Scholar
• Hoyos CM, Yee BJ, Phillips CL, et al. Body compositional and cardiometabolic effects of testosterone therapy in obese men with severe obstructive sleep apnoea: a randomised placebo-controlled trial. Eur J Endocrinol. 2012;167:531–541.
   PubMed Web of Science ®Google Scholar
• Yassin A, Almehmadi Y, Saad F, et al. The Author's Reply: Changing testosterone had no direct effect on HbA1c or weight in diabetic men when TRT was interrupted and then resumed. Clin Endocrinol (Oxf). 2016;85:500–501.
   PubMed Web of Science ®Google Scholar
• Hoyos Camilla M, Killick R, Yee Brendon J, et al. Effects of testosterone therapy on sleep and breathing in obese men with severe obstructive sleep apnoea: a randomized placebo‐controlled trial. Clin Endocrinol (Oxf). 2012;77:599–607.
   PubMed Web of Science ®Google Scholar
• O’Reilly MW, House PJ, Tomlinson JW. Understanding androgen action in adipose tissue. J Steroid Biochem Mol Biol. 2014;143:277–284.
   PubMed Web of Science ®Google Scholar
• Mårin P, Lönn L, Andersson B, et al. Assimilation of triglycerides in subcutaneous and intraabdominal adipose tissues in vivo in men: effects of testosterone. J Clin Endocrinol Metab. 1996;81:1018–1022.
   PubMed Web of Science ®Google Scholar
• Malkin CJ, Pugh PJ, Jones RD, et al. The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men. J Clin Endocrinol Metab. 2004;89:3313–3318.
   PubMed Web of Science ®Google Scholar
• Quarta C, Mazza R, Pasquali R, et al. Role of sex hormones in modulation of brown adipose tissue activity. J Mol Endocrinol. 2012;49:R1–R7.
   PubMed Web of Science ®Google Scholar
• Blouin K, Boivin A, Tchernof A. Androgens and body fat distribution. J Steroid Biochem Mol Biol. 2008;108:272–280.
   Google Scholar
• Wang C, Jackson G, Jones TH, et al. Low testosterone associated with obesity and the metabolic syndrome contributes to sexual dysfunction and cardiovascular disease risk in men with type 2 diabetes. Diabetes Care. 2011;34:1669–1675.
   PubMed Web of Science ®Google Scholar
• Aversa A, Bruzziches R, Francomano D, et al. Effects of testosterone undecanoate on cardiovascular risk factors and atherosclerosis in middle-aged men with late-onset hypogonadism and metabolic syndrome: results from a 24-month, randomized, double-blind, placebo-controlled study. J Sex Med. 2010;7:3495–3503.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. Therapy of endocrine disease: Testosterone supplementation and body composition: results from a meta-analysis study. Eur J Endocrinol. 2016;174:R99–R116.
   PubMed Web of Science ®Google Scholar
• Morton A. Frequent occurrence of hypogonadotropic hypogonadism in type 2 diabetes. J Clin Endocrinol Metab. 2005;90:1903–1903.
   PubMed Web of Science ®Google Scholar
• Laughlin GA, Barrett-Connor E, Bergstrom J. Low serum testosterone and mortality in older men. J Clin Endocrinol Metab. 2008;93:68–75.
   PubMed Web of Science ®Google Scholar
• Wang H, Sun X, Zhao L, et al. Androgen deprivation therapy is associated with diabetes: evidence from meta‐analysis. J Diabetes Investig. 2016;7:629–636.
   PubMed Web of Science ®Google Scholar
• Basaria S, Muller DC, Carducci MA, et al. Relation between duration of androgen deprivation therapy and degree of insulin resistance in men with prostate cancer. Arch Intern Med. 2007;167:612–613.
   PubMedGoogle Scholar
• Choong K, Basaria S. Emerging cardiometabolic complications of androgen deprivation therapy. Aging Male. 2010;13:1–9.
   PubMed Web of Science ®Google Scholar
• Basu R, Man CD, Campioni M, et al. Effect of 2 years of testosterone replacement on insulin secretion, insulin action, glucose effectiveness, hepatic insulin clearance, and postprandial glucose turnover in elderly men. Diabetes Care. 2007;30:1972.
   PubMed Web of Science ®Google Scholar
• Lee C-H, Kuo S-W, Hung Y-J, et al. The effect of testosterone supplement on insulin sensitivity, glucose effectiveness, and acute insulin response after glucose load in male type 2 diabetics. Endocr Res. 2005;31:139–148.
   PubMed Web of Science ®Google Scholar
• Corona G, Giagulli VA, Maseroli E, et al. Testosterone supplementation and body composition: results from a meta-analysis of observational studies. J Endocrinol Investig. 2016;39:967–981.
   PubMed Web of Science ®Google Scholar
• Saad F, Gooren L, Haider A, et al. An exploratory study of the effects of 12 month administration of the novel long-acting testosterone undecanoate on measures of sexual function and the metabolic syndrome. Arch Androl. 2007;53:353–357.
   PubMed Web of Science ®Google Scholar
• Morgentaler A, Dobs AS, Kaufman JM, et al. Long acting testosterone undecanoate therapy in men with hypogonadism: results of a pharmacokinetic clinical study. J Urol. 2008;180:2307–2313.
   PubMed Web of Science ®Google Scholar
• Isidori AM, Giannetta E, Greco EA, et al. Effects of testosterone on body composition, bone metabolism and serum lipid profile in middle‐aged men: a meta‐analysis. Clin Endocrinol (Oxf). 2005;63:280–293.
   PubMed Web of Science ®Google Scholar
• Maggio M, Snyder PJ, De Vita F, et al. Effects of transdermal testosterone treatment on inflammatory markers in elderly men. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol. 2014;20:1170–1177.
   Google Scholar
• Snyder PJ, Bhasin S, Cunningham GR, et al. Lessons from the testosterone trials. Endocr Rev. 2018;2017–00234. DOI: 10.1210/er.2017-00234
   Web of Science ®Google Scholar
• Grossmann M. Testosterone and glucose metabolism in men: current concepts and controversies. J Endocrinol. 2014;220:R37–R55.
   PubMed Web of Science ®Google Scholar
• Hackett G, Cole N, Bhartia M, et al. Testosterone replacement therapy improves metabolic parameters in hypogonadal men with type 2 diabetes but not in men with coexisting depression: the BLAST study. J Sex Med. 2014;11:840–856.
   PubMed Web of Science ®Google Scholar
• Osuna C JA, Gómez-Pérez R, Arata-Bellabarba G, et al. Relationship between BMI, total testosterone, sex hormone-binding-globulin, leptin, insulin and insulin resistance in obese men. Arch Androl. 2006;52:355–361.
   PubMed Web of Science ®Google Scholar
• Rastrelli G, Corona G, Cipriani S, et al. Sex hormone‐binding globulin is associated with androgen deficiency features independently of total testosterone. Clin Endocrinol (Oxf). 2017;88:556–564.
   Web of Science ®Google Scholar
• Saad F, Aversa A, Isidori AM, et al. Testosterone as potential effective therapy in treatment of obesity in men with testosterone deficiency: a review. Curr Diabetes Rev. 2012;8:131–143.
   PubMedGoogle Scholar
• Traish AM, Haider A, Doros G, et al. Long-term testosterone therapy in hypogonadal men ameliorates elements of the metabolic syndrome: an observational, long-term registry study. Int J Clin Pract. 2014;68:314–329.
   PubMed Web of Science ®Google Scholar
• Siddiqui K, Al-Rubeaan K, Nawaz SS, et al. Serum sex hormone binding globulin (SHBG) relation with different components of metabolic syndrome in men with type 2 diabetes. Horm Metab Res. 2018;50:138–144.
   PubMed Web of Science ®Google Scholar
• Ross R. Atherosclerosis – an inflammatory disease. N Engl J Med. 1999;340:115–126.
   PubMed Web of Science ®Google Scholar
• Corrado E, Rizzo M, Coppola G, et al. An update on the role of markers of inflammation in atherosclerosis. J Atheroscler Thromb. 2010;17:1–11.
   PubMed Web of Science ®Google Scholar
• Mazo E, Gamidov S, Sotnikova E. Effects of different treatments on endothelial function in patients with erectile dysfunction and hypogonadism. Ter. Arkh. 2008;80:59–63.
   PubMed Web of Science ®Google Scholar
• Fujimoto R, Morimoto I, Morita E, et al. Androgen receptors, 5 alpha-reductase activity and androgen-dependent proliferation of vascular smooth muscle cells. J Steroid Biochem Mol Biol. 1994;50:169–174.
   PubMed Web of Science ®Google Scholar
• Lin AL, Gonzalez R, Shain SA. Androgen directs apparent cytoplasmic and nuclear distribution of rat cardiovascular androgen receptors. Arterioscler Thromb Vasc Biol. 1985;5:659.
   Google Scholar
• Foresta C, Caretta N, Lana A, et al. Reduced number of circulating endothelial progenitor cells in hypogonadal men. J Clin Endocrinol Metab. 2006;91:4599–4602.
   PubMed Web of Science ®Google Scholar
• Webb CM, McNeill JG, Hayward CS, et al. Effects of testosterone on coronary vasomotor regulation in men with coronary heart disease. Circulation. 1999;100:1690.
   PubMed Web of Science ®Google Scholar
• Kumanov P, Tomova A, Kirilov G, et al. The relationship of plasma endothelin and testosterone levels in male hypogonadism. Fertil Steril. 2004;82:S297.
   Web of Science ®Google Scholar
• Hak AE, Witteman JCM, de Jong FH, et al. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam study. J Clin Endocrinol Metab. 2002;87:3632–3639.
   PubMed Web of Science ®Google Scholar
• Poredos P, Kek A, Verhovec R. Morphological and functional changes of the arterial wall in subject at risk of atherosclerosis and in patients with peripheral arterial occlusive disease. Vasa. 1997;26:271–276.
   PubMedGoogle Scholar
• Morgentaler A, Miner MM, Caliber M, et al. Testosterone therapy and cardiovascular risk: advances and controversies. Mayo Clin Proc. 2015;90:224–251.
   PubMed Web of Science ®Google Scholar
• Rosen RC, Wu FCW, Behre HM, et al. Registry of hypogonadism in men (RHYME): design of a multi-national longitudinal, observational registry of exogenous testosterone use in hypogonadal men. Aging Male. 2013;16:1–7.
   PubMed Web of Science ®Google Scholar
• Bhasin S, Brito JP, Cunningham GR, et al. Testosterone therapy in men with hypogonadism: an Endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1–30.
   PubMed Web of Science ®Google Scholar